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Introduction
Obesity and associated morbidities, such as diabetes, non-alcoholic fatty liver disease, cardiovascular disease and cancer, are among this century's greatest health challenges (Pi-Sunyer, 1999; Cohen et al., 2008; Aballay et al., 2013) . The incidence is increasing and the treatment of obesity is in most cases limited to lifestyle interventions. However, when these fail, bariatric surgery and a few pharmacotherapies are available, although these are only used in cases of severe obesity (Fried et al., 2007) . Furthermore, due to the potential complications of surgery, novel therapies with an improved efficacy in terms of weight loss and reduction of co-morbidities are of great interest (Batterham and Cummings, 2016) .
The most recently developed therapy for obesity is highdose liraglutide, which leads to sustained weight loss at least partially due to a reduction in appetite. Furthermore, liraglutide reduces hyperglycaemia, albeit it is still somewhat limited in terms of efficacy and has challenges on tolerability (Kanoski et al., 2012; Lean et al., 2014) . Another molecule that induces weight loss or at least prevents weight gain is the amylin receptor agonist pramlintide (Aronne et al., 2007) . Pramlintide, due to its appetite regulating capability, has been shown to reduce insulin-induced weight gain, while regulating post-prandial glucose excursions, and therefore has been approved as adjunct therapy to insulin for the treatment of type 2 diabetes (Weyer et al., 2001; Ryan et al., 2009) . However, pramlintide use is limited significantly by lack of potency, and hence, more potent amylin receptor agonists are being explored.
Dual amylin and calcitonin receptor agonists (DACRAs) elicit activation not only of the amylin receptor but also of the calcitonin receptor and have been shown to possess superior activity in terms of activation of the amylin receptor, when compared with classical amylin receptor agonists (Andreassen et al., 2014) . Interestingly, they also activate the receptors for an extended period of time, when compared with the classical agonists, which appears to increase the in vivo efficacy as well as reducing the dosing frequency .
In vivo studies of DACRAs have recently demonstrated a protection against diet-induced weight gain, a reduction in overall adiposity, as well as adipocyte hypertrophy . Furthermore, DACRAs have been shown to improve glucose homeostasis in the diabetic Zucker Diabetic Fatty ZDF-Lepr fa /Crl (ZDF) rats, a phenomenon not observed with selective and less potent amylin receptor agonists (Mack et al., 2010 (Mack et al., , 2011 Andreassen et al., 2014; Hjuler et al., 2015) , while alleviating obesity-derived insulin resistance . Hence, the DACRAs induce amylin receptormediated responses in vivo -reduce food intake, results in weight reduction and suppression of glucagon levels (Roth et al., 2006) , and also have additional beneficial effects on fasting blood glucose and insulin sensitivity. With the limited number of DACRAs available, the search for highly potent molecules in this family has continued, resulting in the development of KBP-089.
In this study, we characterized the effects of KBP-089 on body weight, glucose homeostasis and fatty acid accumulation in liver and muscle tissue. We then investigated whether KBP-089 possesses beneficial effects in addition to inducing substantial weight loss, using a weight-matched group. Finally, we explored the potential effect of KBP-089 on food preference, by comparing the intake of a highly palatable and energy dense diet (chocolate) with that of regular chow in the presence or absence of KBP-089.
Methods

Peptide therapy
Synthetic KBP-089 (American Peptide Company, CA, USA) was dissolved in saline for s.c. delivery. The doses chosen for peptide administration in the current investigations were based on previous comparable DACRA studies in animal models of obesity using potent DACRAs, KBP-042 and KBP-088 Hjuler et al., 2016) .
Animal experiments
All animal procedures were performed in accordance with guidelines from the Animal Welfare Division of the Danish Ministry of Justice under the institutional license issued to Nordic Bioscience (2012-15-2934-00094) . Male Sprague Dawley rats (Harlan, Venray, The Netherlands) and ZDF (Kingston, NY, USA) were obtained at 6 weeks of age and housed (two rats per cage, standard wood chips enriched with red-tinted huts, nest material and sticks) at the Nordic Bioscience animal facility (21-23°C, 55-65% relative humidity, 12 h light/dark cycle) with ad libitum access to food and water. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath & Lilley, 2015) .
Animals
From arrival and throughout the study periods, the high-fat diet (HFD) rats were fed a 60 kcal% fat diet (#58Y1, TestDiet, London, UK), lean normal diet (ND) age-matched rats were fed a standard pelleted chow (#5002, LabDiet, St. Louis, MO, USA) and ZDF rats were fed a Purina Formulab diet (#5008, LabDiet, St. Louis, MO, USA). The rats received food and tap water ad libitum. The HFD and ND rats were nonblindly assigned into experimental groups according to body weight. ZDF rats were non-blindly assigned into experimental groups according to fasting plasma glucose (FPG), glycated haemoglobin (HbA1c) and body weight, ensuring an equal average value of body weight, FPG and HbA1c in the experimental groups at the start of the study. Body weights are visualized as percentage of initial body weight for comparison to other drugs as previously described (Larsen et al., 2001; Mack et al., 2010) . Lean and fat mass data as well as the weight of the different adipose tissues are normalized to the body weight of the individual animal.
Chronic in vivo studies
KBP-089 in HFD rats. After 10 weeks on a high-fat diet, HFD rats were assigned to treatment groups receiving either vehicle (saline s.c.) or KBP-089 (0.625, 1.25 and 2.5 μg·kg À1 , s.c.) once daily in the afternoon with a food restricted pairfed control group for the highest concentration of peptide (n = 10 rats per group in vehicle and KBP-089 treatment groups; n = 9 rats in pair-fed group due to the loss of an animal). Pair-fed animals received an average of the daily intake of food of the 2.5 μg·kg À1 treatment group every day in the afternoon. Food intake and body weight were monitored daily during the initial 2 weeks and once weekly throughout the entire study period. Following 6 and 7 weeks of treatment, p.o. and i.v. glucose tolerance tests (OGTT and IVGTT respectively) were performed in overnight-fasted (12 h) rats with blood glucose measured and EDTA-plasma obtained for hormonal analysis. At the end of the study, animals were killed by being anaesthetized with isoflurane (administered by inhalation) followed by exsanguination and dissection. Retroperitoneal, epididymal and s.c. inguinal fat were surgically removed and weighed. Overnight-fasted blood samples were collected for basal plasma hormonal analyses.
KBP-089 in ZDF rats
The day prior to dosing initiation, 20 ZDF rats were assigned to two groups (n = 10 rats per group) receiving either vehicle (saline, s. (Matthews et al., 1985) .
HOMA-IR was developed for humans; however, it can be used as a surrogate measurement for insulin resistance in rodents (Cacho et al., 2008; Mather, 2009 ).
Weight-matched HFD rats. To address KBP-089 efficacy independent of weight loss, we did a 6 week study in HFD rats (n = 12) with a weight-matched group to the 2.5 μg·kg
À1
KBP-089 group. Food intake and body weight were monitored daily throughout the study period, and in order to match the body weights, we estimated the food restriction needed to achieve a comparable weight reduction based on pilot studies (data not shown) and adjusted estimations to body weight on a daily basis. The rats were subjected to an OGTT after 3 weeks of treatment. The rats were weighed and scanned for body composition (EchoMRI4in1; EchoMRI, Houston, TX, USA) at study end and killed as for the chronic in vivo studies.
Food preference in ND rats. To assess the effect of KBP-089 on the preference of diet, ND rats were offered normal chow or chocolate (milk chocolate with hazelnuts) (Marabou, Mondelez Danmark, Brøndby, Denmark). The animals were allowed to accustom to the chocolate for 1 week before injections with 2.5 μg·kg
KBP-809 were initiated. Voluntary food and chocolate intake were monitored for 24 h after treatment for 7 days. 
Glucose tolerance tests
Insulin tolerance test
ZDF rats (fasted for 6 h) were administered with KBP-089 at t = À30 and received intraperitoneal insulin (1.0 U·kg À1 ) at t = 0, and blood glucose was measured subsequently at t = 0, 30, 60 and 120 min after insulin injection. The data are visualized as percentage of initial blood glucose for simplicity.
Fat accumulation in liver and muscle tissue
To address tissue fat accumulation, the liver and gastrocnemius muscle were surgically removed for optimal cutting temperature compound embedding, snap frozen on ice/ethanol, stored at À80°C until cryosectioning. Tissue sections were stained with oil red O stain, and images were captured with a light microscope (magnification of ×40 for gastrocnemius and ×20 for liver, nine images per animal; three pictures per depth) and quantified using ImageJ capable of calculating the amount of red pixels in relation to μm 2 as previously described (Mehlem et al., 2013) and, for simplicity, were visualized as the fold-induction from lean rats.
Biochemical analysis
Blood samples were collected in EDTA tubes and centrifuged at 1850 × g for 10 min at 4°C. Blood glucose was monitored by Accu-Check® Avia monitoring system (Roche Diagnostics, Rotkreuz, Switzerland). HbA1c was measured using an automatized DCA Vantage Analyzer (Siemens AG, Erlangen, Germany). Plasma levels of insulin (Mercodia Rat Insulin ELISA, Mercodia AB, Uppsala, Sweden) were analysed according to the manufacturer's instruction.
Statistical analysis
All data are presented as means ± SEM. The statistical analysis of various drug effects were conducted using one-way ANOVA followed by Tukey's post test for multiple comparison for parametric data and Kruskal-Wallis test with Dunn's post test for non-parametric data if F achieved the necessary level of statistical significance (P < 0.05). Lean age-matched controls are compared with HFD vehicle, and ZDF vehicle with ZDF KBP-089, using Student's t-test. All analyses were performed using GraphPad Prism software (GraphPad Prism, San Diego, CA, USA). A value of P < 0.05 was considered statistically significant. The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Results
KBP-089 potently reduces appetite, body weight and fat depots
High-fat feeding resulted in a phenotype with significantly increased body weight (596 ± 12 vs. 545 ± 8 g, P < 0.05), hyperinsulinaemia (1.9 ± 0.1 vs. 0.9 ± 0.1 ng·mL À1 , P < 0.05), impaired glucose control without hyperglycaemia (OGTT tAUC 1343 ± 18.1 vs. 1259 ± 17.1, P < 0.05) and impaired insulin sensitivity (HOMA-IR) (11.3 ± 0.3 vs. 4.3 ± 0.3, P < 0.05), compared with the lean age-matched controls. Thus, the HFD rats resembled an obese and prediabetic phenotype as expected from previous studies Gydesen et al., 2016) .
To investigate the anti-obesity potential of KBP-089 in vivo, we treated HFD rats for 8 weeks. Previously, DACRAs have been shown to induce hypophagia Gydesen et al., 2016) ; therefore, a pair-fed group to the highest concentration of KBP-089 was included to explore the impact of food restriction on body weight. KBP-089 was s.c. administered in three doses (0.625, 1.25 and 2.5 μg·kg À1 )
for 56 days. Food intake was transiently attenuated by KBP-089 ( Figure 1A ), albeit cumulative food intake after the initial 2 weeks of treatment was not significantly different in 2.5 μg·kg À1 treated rats compared with vehicle rats (504 ± 35 vs. 408 ± 19 g per animal). 8 weeks of KBP-089 treatment resulted in a dose-dependent and sustained 17 ± 1.7 % weight loss in the 2.5 μg·kg À1 group ( Figure 1B) , while pairfeeding resulted in a 4 ± 2.0 % body weight reduction. Based on food intake and body weight change, food efficiency was calculated. Expectedly, treatment with KBP-089 markedly attenuated the food efficiency compared with vehicle and the pair-fed group ( Figure 1C) . Epididymal, inguinal and perirenal fat pads were weighed, and in conjunction with the significant body weight reduction, the weight of the adipose tissues was significantly reduced after treatment with KBP-089 ( Figure 1D-F) . This reduction was not observed in the pair-fed control rats.
KBP-089 enhances glucose tolerance and potentially insulin sensitivity
An OGTT was performed after 6 weeks of treatment and followed by an IVGTT allowing circumvention of the influence of the gastrointestinal tract and thereby assessment of peripheral glucose tolerance after 7 weeks of treatment ( Figure 2) . In contrast to previous DACRA studies Gydesen et al., 2016) , the rats were not dosed 30 min prior to the glucose challenge to avoid the strong effect on gastric emptying. In both tests, all treatment groups showed a trend towards lower blood glucose levels compared with vehicle and pair-fed controls 5 min (IVGTT) and 15 min (OGTT) after glucose administration (Figure 2A, D) . However, tAUC was not significantly changed for either test when compared with vehicle or pair-fed controls ( Figure 2B, E) . Interestingly, the glucose-induced insulin hyper secretion observed in vehicle and pair-fed groups was markedly and dosedependently suppressed by KBP-089 during both OGTT and IVGTT, which resulted in significantly reduced insulin AUC values in KBP-089 treated rats ( Figure 2C, F) . Pair feeding did not improve glucose tolerance or hyperinsulinaemia in either test.
KBP-089 reduces the accumulation of lipids in both muscle and liver
After treatment with KBP-089 for 56 days, lipid accumulation was assessed in liver and muscle tissue. As seen in Figure 3 , high-fat feeding led to increased lipid accumulation in both liver and muscle compared with lean agematched controls. This inappropriate storage of lipids was completely eliminated by treatment with 2.5 μg·kg À1 KBP-089, despite the rats having been on HFD for 10 weeks prior to initiation of therapy. Importantly, this effect was not obtained by pair-feeding.
KBP-089 lowers glycaemia and increases glucose tolerance and insulin action in ZDF rats
We tested the anti-hyperglycaemic efficacy of KBP-089 in vivo in ZDF rats for 8 weeks (5 μg·kg À1 for 4 weeks, 20 μg·kg À1 for additional 4 weeks, s.c.). In ZDF rats, fasting blood glucose levels were decreased significantly (6.9 ± 0.7 mM, P < 0.05) over 7 weeks by KBP-089 treatment compared with vehicle, resulting in HbA1c reduction by~2.5 ± 0.2% compared with vehicle at the end of the study ( Figure 4A , B). Glucose tolerance was tested by an OGTT where treatment with KBP-089 resulted in a moderate glucose reduction compared with vehicle. The tAUC was lowered significantly (~30%, P < 0.05). Insulin action was assessed in an insulin tolerance test which manifested in a significant larger drop in blood glucose in response to insulin in KBP-089-treated rats compared with vehicle (tAUC~19%, P < 0.05), supporting increased insulin sensitivity.
KBP-089 induces metabolic improvements in addition to those induced by weight loss through food restriction
In order to evaluate drug-induced metabolic improvements beyond what a weight loss can do, we performed a study with a weight-matched control in which weight reductions were induced either by KBP-089 administration ('KBP-089') or by food restriction alone ('Pair weighed'/'PW'). In order to match the body weights, the pair-weighed rats received significantly less food compared with the KBP-089-treated rats ( Figure 5A ). As in the previous study, body weight was BJP S Gydesen et al.
significantly reduced by KBP-089 administration, and this was matched during the study in the pair-weighed group ( Figure 5B ). There was no significant difference between the groups in body weight at study start (vehicle: 409 ± 3 g, KBP-089: 410 ± 3 g and PW: 408 ± 4 g). During the study, the body weight was significantly reduced in KBP-089 and pair-weighed rats, albeit there was no difference between KBP-089-treated rats and the pair-weighed rats (vehicle: 462 ± 6 g, KBP-089: 398 ± 4 g and PW: 403 ± 6 g). Interestingly, the epididymal and perirenal adipose tissues, which are directly associated with visceral adiposity and insulin resistance (Gabriely et al., 2002) , were significantly lower in the ). Relative weight of (D) epididymal, (E) inguinal and (F) peritoneal adipose tissue at study end. (n = 10 rats per group in vehicle and KBP-089 treatment groups; n = 9 rats in pair-fed group). AT, adipose tissue. Statistical analysis between groups was evaluated by an ordinary one-way ANOVA with Tukey's multiple comparisons test. *P < 0.05. compared with vehicle, ¤P<0.05 compared with pair-fed.
KBP-089 and the pair-weighed group compared with vehicle ( Figure 5C ). There was no significant difference between the surgically removed adipose tissues in KBP-089-treated rats and the pair-weighed rats; however, there was a trend towards a more distinct reduction in adipose tissue in KBP-089-treated rats compared with pair-weighed rats. Using MR, we found a slight increase in lean body mass in KBP-089-treated rats compared with vehicle rats, and a reduced amount of whole body fat mass in KBP-089-treated and pair-weighed rats compared with vehicle ( Figure 5D ), indicating that the weight loss occurs primarily in fat tissue. As expected, KBP-089 again caused improved glucose tolerance with significantly lowered plasma insulin levels (Figure 5D , E, G, H) compared with vehicle. Surprisingly, the pair-weighed group did not show a marked improvement in glucose tolerance despite the significant weight reduction. Food restriction alone had significantly ameliorated hyperinsulinaemia during OGTT ( Figure 5H) ; however, it was still significantly higher compared with KBP-089. Finally, KBP-089-treated rats had a reduced rate of gastric emptying compared with vehicle and Figure 2 KBP-089 enhances glucose tolerance and potentially insulin sensitivity in HFD rats. (A, D) Plasma glucose during OGTT and IVGTT in high-fat diet fed rats treated with KBP-089 (0.625, 1.25 and 2.5 μg·kg À1 ) for 6 and 7 weeks respectively. Total AUC for (B, E) glucose and (C, F) plasma insulin during OGTT and IVGTT after 6 and 7 weeks respectively (n = 10 rats per group in vehicle and KBP-089 treatment groups; n = 9 rats in pair-fed group). Statistical analysis between groups was evaluated by (B, C, F) an ordinary one-way ANOVA with Tukey's multiple comparisons test and (E) Kruskal-Wallis test with Dunn's multiple comparisons test. *P < 0.05 compared with vehicle, ¤P < 0.05compared with pair-fed.
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pair-weighed rats (data not shown) as previously observed with DACRA treatment .
KBP-089 induces changes in food preference
To examine the effect of the reduced food intake in detail, a food preference test was performed (Figure 6 ). When the rats had access to ad libitum chow and chocolate (as compared with chow alone), caloric intake was significantly increased. Furthermore, chow intake was significantly reduced as the rats preferred the chocolate and obtained 74% of their calories from chocolate [caloric intake vehicle/chow: 143 ± 3.0 kcal, caloric intake of vehicle/chow + chocolate: 173 ± 8.1 kcal (chow = 46.1 ± 2.9 kcal and chocolate = 127.3 ± 9.8 kcal)]. KBP-089 administration was associated with a significantly reduced caloric intake, -34% compared with vehicle treatment; caloric intake of KBP-089/chow + chocolate: 115 ± 10.7 kcal (chow =74 ± 6.6 kcal, chocolate =41.4 ± 9.4 kcal), accompanied by a relative increase in chow consumption and a drastic reduction in chocolate consumption (127.3 ± 9.8 kcal vs. 41.4 ± 9.4 kcal).
Figure 3
KBP-089 reduces the accumulation of lipids in both muscle and liver in HFD rats. Oil Red O stained frozen (A) liver sections and (B) gastrocnemius muscle (magnification of ×20 for liver and ×40 for gastrocnemius, nine images per animal; three pictures per depth) in (1) ND rats, (2) vehicle HFD rats, (3) 2.5 μg·kg À1 KBP-089, (4) pair-fed to 2.5 μg·kg À1 KBP-089 and (5) quantification of the results (n = 10 rats per group in vehicle and KBP-089 treatment groups; n = 9 rats in pair-fed group). Data are expressed as fold of lean. Statistical analysis between groups was evaluated by a Kruskal-Wallis test with Dunn's multiple comparisons test. *P < 0.05 compared with vehicle, ¤P < 0.05 compared with pair-fed.
Discussion
The present study describes a novel DACRA, called KBP-089, which is able to induce and sustain a significant weight loss irrespective of food intake. Importantly, KBP-089 possesses the ability to improve glucose tolerance above what can be obtained with weight loss alone. Treatment with KBP-089 reduced food intake initially. However, this effect was reduced during the course of the study, and the effects obtained with KBP-089 treatment on weight, glucose tolerance, adipose tissue reduction and removal of ectopic lipid depositions in liver and muscle were not achieved with pair-feeding, clearly demonstrating effects of KBP-089 beyond appetite restriction. The weight reducing effect and the effect on food intake can most likely be attributed to central amylin receptor activation. It has previously been demonstrated that amylin facilitates a reduction in body weight that cannot only be attributed to suppression of food intake (Isaksson et al., 2005; Roth et al., 2006) . An interesting aspect of the reduction in fatty acid accumulation in the liver is the known relationship between liver fat, insulin resistance and non-alcoholic steatohepatitis (Cusi, 2009; Milić et al., 2014) , and these data indicate that KBP-089, at least due to its weight reducing capacity, could be a novel treatment candidate for liver steatosis. Novel DACRA, KBP-089, reduces body weight and fat deposition BJP
The KBP-089-mediated changes in adiposity were confirmed in the pair-weight study where KBP-089-treated rats had significantly lower epididymal, inguinal and perirenal adipose tissues compared with vehicle-treated rats, and trends towards lowered adiposity compared with pairweighed adipose tissues -despite the same body weight. This could indicate that KBP-089 treatment results in a loss of fat mass rather than lean body mass. Food restriction alone is however not sufficient to obtain the same reduction in adipose depots. As mentioned above, amylin agonism has long been associated with an increase in respiratory quotient, which is associated with a preferential oxidation of fat (Wielinga et al., 2010) . Moreover, other studies have also associated activation of amylin receptors with a specific reduction in fat mass rather than lean mass (Roth et al., 2006 (Roth et al., , 2007 , whereas inhibiting amylin signalling centrally increases fat mass (Rushing et al., 2001) , thus potentially explaining the difference in fat depots in this study. This was tested using MR scanning. There was no difference in whole body fat mass between the KBP-089-treated and pair-weighed rats; however, in support of the limited loss of lean mass, we found a slightalbeit significant -increase in lean mass in KBP-089-treated rats compared with vehicle rats, underscoring that the weight loss is primarily mediated through a reduction in adipose tissue weight. Furthermore, the slight increase in lean mass is a positive effect, as heavy weight loss in many cases is associated with loss in lean body mass in humans (Garthe et al., 2011; Weiss et al., 2016) .
In terms of hyperglycaemia and insulin resistance, amylin analogues have shown promise (Ratner et al., 2004; Mack et al., 2011) ; however, they do not possess the intrinsic ability to reduce fasting plasma glucose levels and insulin tolerance, in contrast to KBP-089 as shown here in both ZDF and HFD rats, or other DACRAs . These data are further corroborated by the pair-weight study where substantially lower glucose and insulin levels were observed during glucose tolerance tests, in the KBP-089 treatment group when compared with the weight-matched group. The improvement in insulin levels also manifested as an improvement in glucose control too; however, the possibility that the PW animals had an 'artificial' increase in glucose intolerance due to prolonged fasting (or significant food restriction) cannot be out ruled, although they did not show any signs of malnutrition or ill behaviour. The lowering of insulin levels could be attributed to the lack of improvement in glucose tolerance when compared with the improvement observed in KBP-089-treated rats, which would have been likely after a significant weight loss (Horton and Hill, 2001; Lafontan and Langin, 2009; Karpe et al., 2011) . The KBP-089-induced improvement in glucose tolerance is partly mediated through the lowering of gastric emptying rate, as previously observed with amylin agonism (Young et al., 1995; Young, 2005) . In an p.o. glucose tolerance test without dosing prior to the glucose challenge (data not shown), glucose tolerance was slightly improved in KBP-089-treated rats, and insulin levels were significantly lowered compared with vehicle rats, while PW animals mimic glucose tolerance and insulin levels as demonstrated in the OGTT. These data further indicate the strong insulinostatic effect of KBP-089.
Another important way to regulate body weight could be to manipulate volunteer food intake/composition of food in the brain. This was hypothesized to be relevant for KBP-089 due to a known effect of amylin agonism on the release of dopamine in the hypothalamus (Brunetti et al., 2002) and alterations in the melanocortigenic system, (Roth et al., 2012) both of which are mediators of the reward/pleasure circuits known to affect feeding patterns (Pandit et al., 2016) . Normally, amylin does not produce conditioned taste aversion (Lutz et al., 1995; Rushing et al., 2002) ; hence, this is not normally used to explain the alterations in food intake. Alternatively, the reduced impulse to consume sugar instead of normal chow could be explained in other ways. In humans, patients treated with pramlintide also experience a voluntary shift in eating behaviour and 'binge eating' (Smith et al., 2007) . A change of food intake towards a more healthy diet (less energy dense and sweet) is also observed in patients after surgical weight intervention (Mathes and Spector, 2012) . The mechanisms behind this are not clear; however, alterations in food reward or taste functions have been suggested as possible explanations (Miras and le Roux, 2014) . From the food preference study presented here, it could be speculated that dosing with KBP-089 offers some of the effects obtained by surgical interventions, making KBP-089 a relevant option for treating severely obese patients and thereby aiding a significant weight loss along with a change in lifestyle, which might improve the results even further.
In conclusion, the novel DACRA KBP-089 induces and sustains a substantial weight loss in obese rats and reduces overall adiposity and ectopic lipid accumulation in the liver. In addition, KBP-089 improved glucose tolerance and indirectly improved insulin action independent of food intake and body weight, hence revealing the potential of KBP-089 as an anti-obesity agent with additional benefits on glucose control and liver steatosis. 
